4DMedical Ltd (ASX:4DX) shares soared 11.53% during intraday trading, driven by the company's announcement of robust fiscal 2026 operating results that highlighted accelerating revenue growth and expanding global adoption of its lung imaging technology.

The company reported operating revenue of AU$7.2 million for fiscal 2026, representing a 23% increase year-on-year, fueled by a significant rise in paid scan volumes. 4DMedical's software-as-a-service products are now live at 540 sites globally, up 39% from the prior year, with a record fourth quarter delivering 105,970 scans — a 43% jump compared to the same period last year.

Investor sentiment was further bolstered by the company's strong cash position of AU$278 million as of June 30, and the completion of the Contextflow acquisition following all necessary regulatory approvals. The addition of the European lung imaging AI company is expected to enhance 4DMedical's product portfolio and expand its international footprint.